Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication
Riccardo G. Borroni(Policlinico San Matteo Fondazione), Rita De Sanctis(Humanitas University), Alessandra Solferino(IRCCS Humanitas Research Hospital), Mariangela Gaudio(Humanitas University), Riccardo Gerosa(Humanitas University), Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Sofia Manara(IRCCS Humanitas Research Hospital), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Michela Bartolini(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), C. Benvenuti
Cited by 9
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532